米格列醇联合二甲双胍治疗2型糖尿病的临床效果观察

Efficacy observation of miglitol combined with metformin in the treatment of type 2 diabetes mellitus

目的观察米格列醇联合二甲双胍治疗2型糖尿病的临床效果。方法选取医院收治的2型糖尿病患者124例,随机分为对照组和观察组,每组62例。对照组给予二甲双胍治疗,观察组在此基础上联合米格列醇治疗。观察2组治疗前后糖化血红蛋白(Hb A1c)、血清胰高血糖素(PG)及氧化应激因子[丙二醇(MDA)、谷胱甘肽过氧化物酶(GSH-Px)]水平,并统计2组临床治疗效果。结果治疗前,2组Hb A1c、PG及MDA、GSH-Px水平差异无统计学意义(P>0.05);经治疗,观察组Hb A1c、PG、MDA低于对照组,GSH-Px高于对照组,差异均有统计学意义(P<0.05)。观察组治疗总有效率为98.39%,高于对照组的87.10%(P<0.05)。结论 2型糖尿病患者采用米格列醇联合二甲双胍治疗,可有效降低患者Hb A1c、PG水平,减轻氧化应激反应,临床效果显著。

Objective To investigate the clinical effect of miglitol and mefformin in treatment of type 2 diabetes. Methods 124 cases of type 2 diabetes mellitus patients in our hospital were selected and randomly divided into control group and observation group, each of 62 cases. The control group was given mefformin for treatment, the observation group added miglitol for treatment on the basis of the control group. Compared the gtycosylated hemoglobin （HbAlc）, serum glucagon （PG） and the level of oxidative stress factor[ propylene glycol （MDA）, glutathione peroxidase （GSH-Px）] in the two groups before and after the treatment. And then doing statistical analysis on the clinical efficacy. Results Before treatment, there was no significant difference in the levels of HbA1 c, PG, GSH-Px and MDA between the two groups （ P 〉 0.05 ） ; after treatment, the HbAlc, PG and MDA of the observation group were lower than the control group,but GSH-Px was higher than that of the control group ,the difference was statistically significant （P 〈0.05 ）. The total effective rate of treatment group was 98.39%, which was higher than 87. 10% of the control group, the difference was statistically significant （P 〈 0.05 ）. Conclusion Miglitol combined with mefformin in patients with type 2 diabetes, can effectively reduce the PG, HbAlc level of patients, and reduce the oxidative stress reaction,the clinical effect of which is remarkable.